reported that when the cutoff was ≥10%, ≥50%, and ≥90%, the CD8+ rates in the tumor center and invasive front of the tumors were 54% vs. 53.5%, 8.2% vs. 8.8%, and 0 vs. 0, respectively (37). The gene discussed is CD8A; the disease is neoplasm.